Have a personal or library account? Click to login
Serum Uric Acid Concentration in Overweight and Obese Women with Polycystic Ovary Syndrome / Nivelul acidului uric la femeile supraponderale și obeze cu sindromul ovarelor polichistice Cover

Serum Uric Acid Concentration in Overweight and Obese Women with Polycystic Ovary Syndrome / Nivelul acidului uric la femeile supraponderale și obeze cu sindromul ovarelor polichistice

Revista Romana de Medicina de Laborator
Volume 23 (2015): Issue 1 (March 2015)
By: Letiția Elena Leuștean,  Cristina Dimitriu,  Simona Fica,  Maria-Christina Ungureanu,  Cristina Preda,  Voichița Mogoș,  Didona Ungureanu and  Carmen Vulpoi  
Open Access
|Mar 2015

References

  1. 1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9. DOI: 10.1210/jc.2003-03204610.1210/jc.2003-03204615181052
    Search in Google Scholar
  2. 2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434-8. DOI: 10.1210/jc.85.7.2434 DOI: 10.1210/jcem.85.7.668210.1210/jc.85.7.2434
    Search in Google Scholar
  3. 3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-6. DOI: 10.1056/NEJMra04153610.1056/NEJMra04153615788499
    Search in Google Scholar
  4. 4. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-61. DOI: 10.1056/ NEJM19950928333130710.1056/NEJM1995092833313077651477
    Search in Google Scholar
  5. 5. Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res. 2007;68(5):209-17. DOI: 10.1159/00010153810.1159/000101538428725217426408
    Search in Google Scholar
  6. 6. Kousta E, Tolis G, Franks S. Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences. Hormones 2002;4(3):133-147. DOI: 10.14310/horm.2002.1115110.14310/horm.2002.1115116613823
    Search in Google Scholar
  7. 7. Cucuianu M, Brudasca I. Gout, hyperuricemia and the metabolic syndrome. Rev Romana Med Lab. 2012;20(3):199-206.
    Search in Google Scholar
  8. 8. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39-42. DOI: 10.1016/j.semnephrol. 2004.09.007
    Search in Google Scholar
  9. 9. Vuonnen-Markkola H, Yki-Jamnen H. Hyperuncemia and insulin resistance. J Clin Endocrinol Metab. 1995;78:25-9. DOI: 10.1210/jcem.78.1.828870910.1210/jcem.78.1.82887098288709
    Search in Google Scholar
  10. 10. Antilla L, Rouru J, Penttila T, Irjala K. Normal serum uric acid concentrations in women with polycystic ovary syndrome. Hum Reprod. 1996;11:2405-7. DOI: 10.1093/oxfordjournals.humrep.a01912410.1093/oxfordjournals.humrep.a0191248981120
    Search in Google Scholar
  11. 11. Luque-Ramirez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF. Serum uric acid concentration as a non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Hum Rep. 2008;23(7):1594-601. DOI: 10.1093/humrep/den09510.1093/humrep/den09518375410
    Search in Google Scholar
  12. 12. Quinonez Zarza C, Silva Ruiz R, Torres Juarez JM. Obesity, arterial hypertension, metabolic disorders, and polycystic ovary syndrome. Ginecol Obstet Mex. 2000;68:317-22.
    Search in Google Scholar
  13. 13. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.00410.1016/j.fertnstert.2003.10.00414711538
    Search in Google Scholar
  14. 14. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816-26. DOI: 10.1016/j.amjmed.2005.03.04310.1016/j.amjmed.2005.03.04316084170
    Search in Google Scholar
  15. 15. Johnson R, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-90. DOI: 10.1161/01.HYP.0000069700.62727.C510.1161/01.HYP.0000069700.62727.C512707287
    Search in Google Scholar
  16. 16. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932-5. DOI: 10.1016/j.amjcard. 2004.06.032
    Search in Google Scholar
  17. 17. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221-6. DOI: 10.1161/01.CIR.0000022140.61460.1D10.1161/01.CIR.0000022140.61460.1D12105162
    Search in Google Scholar
  18. 18. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030. DOI: 10.1210/er.2011-103410.1210/er.2011-1034539315523065822
    Search in Google Scholar
  19. 19. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E628-37. DOI: 10.1210/jc.2012-390810.1210/jc.2012-390823476073
    Search in Google Scholar
  20. 20. Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C, et al. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J Clin Endocrinol Metab. 2013;98:2581-8. DOI: 10.1210/jc.2013-116110.1210/jc.2013-116123596136
    Search in Google Scholar
  21. 21. Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008;69(1):52-60. DOI: 10.1111/j.1365-2265.2007.03145.x10.1111/j.1365-2265.2007.03145.x18034780
    Search in Google Scholar
  22. 22. Ketel IJG, Stehouwer CDA, Serne EH, Korsen TJM, Hompes PGA, Smulders YM, et al. Obese but not normal- weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metab. 2008;93(3):3365-72. DOI: 10.1210/jc.2008-062610.1210/jc.2008-062618593766
    Search in Google Scholar
  23. 23. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004;59(2):141-54. DOI: 10.1097/01.OGX.0000109523.25076.E210.1097/01.OGX.0000109523.25076.E214752302
    Search in Google Scholar
  24. 24. Tsilchorozidou T, Overton C, Conway G. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol. 2004;60(1):335-45. DOI: 10.1046/j.1365-2265.2003.01842.x10.1046/j.1365-2265.2003.01842.x14678281
    Search in Google Scholar
  25. 25. Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013;78(8):773-6. DOI: 10.1016/j.steroids. 2013.04.009
    Search in Google Scholar
  26. 26. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(4):1357-63. DOI: 10.1210/jc.2005-243010.1210/jc.2005-2430
    Search in Google Scholar
  27. 27. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: result of a 31 year follow-up study. Hum Fertil. 2000;3(2):101-5. DOI: 10.1080/146472700200019878110.1080/1464727002000198781
    Search in Google Scholar
  28. 28. Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(2):112-26. DOI: 10.1093/humupd/dmr04610.1093/humupd/dmr046
    Search in Google Scholar
  29. 29. Vryonidou A, Papatheodorou A, Tavridou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(5):2740-6. DOI: 10.1210/jc.2004-236310.1210/jc.2004-2363
    Search in Google Scholar
  30. 30. Rizzo M, Berneis K, Herberger M, Pepe I, Di Fede G, Rini GB, et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod. 2009;24(9):2286-92. DOI: 10.1093/humrep/dep12110.1093/humrep/dep121
    Search in Google Scholar
  31. 31. Barber TM, McCarthy MI, Wass AH, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol. 2006;65(2):137-45. DOI: 10.1111/j.1365-2265.2006.02587.x10.1111/j.1365-2265.2006.02587.x
    Search in Google Scholar
  32. 32. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2(4):232-9.
    Search in Google Scholar
  33. 33. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulinresistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165-74. DOI: 10.2337/diabetes.38.9.1165 DOI: 10.2337/diab.38.9.116510.2337/diabetes.38.9.1165
    Search in Google Scholar
  34. 34. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators of inflammation vol. 2010, article ID 758656, doi:10.1155/2010/758656 Hindawi Publishing Corporation. DOI: 10.1155/2010/75865610.1155/2010/758656
    Search in Google Scholar
  35. 35. Chen X, Jia X, Qiaol J, Guan Y, Kang J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol. 2013;50:R21-R37. DOI: 10.1530/JME-12-024710.1530/JME-12-0247
    Search in Google Scholar
  36. 36. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol. 2002;2:126-30. DOI: 10.1016/S1471-4892(02)00143-110.1016/S1471-4892(02)00143-1
    Search in Google Scholar
  37. 37. Vizzotto L, Vartemati M, Marinello E, Leoncini R, Pagani R, Pizzichini M. Effect of testosterone on purine metabolism and morphometric parameters in the rat liver. Mol Cell Endocrinol. 1996;119:123-7. DOI: 10.1016/0303-7207(96)03797-510.1016/0303-7207(96)03797-5
    Search in Google Scholar
  38. 38. Marinello E, Leoncini R, Terzouli L, Vannoni D, Porcelli B, Resconi G. Effect of testosterone on purine nucleotide metabolism in rat liver. Horm Metab Res. 2004;36:614-9. DOI: 10.1055/s-2004-82592310.1055/s-2004-82592315486812
    Search in Google Scholar
  39. 39. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow- up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404-10. DOI: 10.1001/jama.283.18.2404 10.1001/jama.283.18.240410815083
    Search in Google Scholar
DOI: https://doi.org/10.1515/rrlm-2015-0010 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 107 - 114
Submitted on: Nov 18, 2014
|
Accepted on: Mar 3, 2015
|
Published on: Mar 25, 2015
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
PCOS,
uric acid,
obesity,
insulin,
HOMA-IR
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2015 Letiția Elena Leuștean, Cristina Dimitriu, Simona Fica, Maria-Christina Ungureanu, Cristina Preda, Voichița Mogoș, Didona Ungureanu, Carmen Vulpoi, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 23 (2015): Issue 1 (March 2015)Next article